Longeveron is initiating a Phase 2a clinical trial for its Lomecel-B treatment — an investigational, bone marrow-derived, medicinal signaling cell (MSC) — in patients with mild Alzheimer’s disease. The first patient has already given consent to participate in the trial, and further patient screening has begun. “We are pleased to have initiated this Phase 2a trial, as this study is intended to build upon the Phase 1 results and marks an important milestone in our…
You must be logged in to read/download the full post.
The post Phase 2a Trial Initiated for Lomecel-B in Mild Alzheimer’s Disease appeared first on BioNewsFeeds.